VC23

Codetta Bio is a life sciences company that has developed a novel multi-omic analysis platform utilizing digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsIPCR). This integrated platform combines reagents, hardware, and software to facilitate multiplexed liquid biopsy and the analysis of isolated DNA, RNA, and proteins. By offering a quantitative and efficient solution for biomarker measurement, Codetta Bio aims to help researchers understand the complex interplay of genetic, environmental, lifestyle, and clinical factors affecting individual health. The platform's capabilities allow for simultaneous detection of multiple analytes, enabling more effective analysis of viral and bacterial targets, mutations, and gene and protein expression. Ultimately, Codetta Bio seeks to accelerate the development of next-generation therapies, thereby enhancing patient care and quality of life.

Fluent BioSciences is a life science company focused on single-cell technology, specializing in molecular analysis of cells without the need for complex microfluidic instrumentation. Its proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the rapid self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative technology enhances accessibility to single-cell, molecule, and protein analysis, thereby broadening market access for researchers in biotechnology, pharmaceuticals, and academic institutions.

Tangen Biosciences LLC is focused on developing a molecular diagnostics platform that facilitates rapid and accurate detection of specific DNAs and RNAs. Utilizing a rotary rapid isothermal nucleic acid detection technique, the platform operates without the need for laboratory facilities, allowing for direct detection from specimens. This innovation enables healthcare providers to conduct precise and cost-effective DNA nucleic tests, enhancing diagnostic capabilities in various clinical settings. The technology offers the specificity and sensitivity comparable to traditional polymerase chain reaction (PCR) methods, thereby improving the efficiency of nucleic acid detection in medical diagnostics.